Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Other Non Operating Income data on record, last reported at $362000.0 in Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 130.57% year-over-year to $362000.0; the TTM value through Dec 2025 reached -$700000.0, up 42.34%, while the annual FY2025 figure was -$700000.0, 42.34% up from the prior year.
  • Other Non Operating Income reached $362000.0 in Q4 2025 per AMLX's latest filing, up from -$181000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $362000.0 in Q4 2025 and bottomed at -$747000.0 in Q1 2024.
  • Average Other Non Operating Income over 5 years is -$158800.0, with a median of -$111000.0 recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 187.67% in 2022, then crashed 1278.95% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$59000.0 in 2021, then crashed by 1067.8% to -$689000.0 in 2022, then skyrocketed by 124.82% to $171000.0 in 2023, then fell by 8.19% to $157000.0 in 2024, then surged by 130.57% to $362000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $362000.0 in Q4 2025, -$181000.0 in Q3 2025, and -$546000.0 in Q2 2025.